Lost in Translation: Why Scientists Can't Pitch — and Why That Is Everyone's Problem

A neuroscientist at a Belgian university spent three years developing a diagnostic algorithm capable of detecting early-stage Parkinson's disease from routine gait analysis — work that had cleared peer review, attracted favourable attention at two clinical conferences, and been independently validated by a hospital partner. When she stood before a panel of deep-tech investors to present the opportunity, she opened with fourteen slides on the neurological mechanisms underlying the disease. She included five figures from her published papers. She used the phrase "statistically significant" eleven times. She did not mention the size of the diagnostic market, the competitive landscape, the reimbursement pathway, or what she needed the investment to accomplish. The panel passed. She did not understand why.

Her experience is not a story of incompetence. It is a story of preparation for the wrong room. The skills that produce a successful scientific presentation — methodological rigour, epistemic caution, precise qualification of claims, exhaustive acknowledgement of limitations — are almost perfectly calibrated to undermine a successful investor pitch. Understanding why these two communication forms are so structurally opposed is essential to understanding why the gap between them costs science so much.

The divergence has deep roots. Academic communication norms were formalised gradually across the seventeenth and eighteenth centuries, as the institutions of peer review and scientific publication emerged from correspondence networks among natural philosophers. Their core logic was adversarial in the best sense: every claim should be made as precisely as possible, every alternative explanation entertained, every weakness acknowledged before a critic could exploit it. A researcher who overstated their findings was not merely wrong — they were violating the fundamental compact of the enterprise. Hedging was not weakness; it was intellectual honesty made visible.

Investment communication developed under entirely different evolutionary pressures. Venture capital, in its modern form, emerged in the United States in the late 1940s and grew rapidly through the 1970s and 1980s as the vehicle for funding technology commercialisation. Its communication norms — the pitch deck, the executive summary, the elevator pitch — were shaped by the need to make rapid decisions under radical uncertainty, with large numbers of competing opportunities and limited time. In this environment, the ability to project conviction, simplify ruthlessly, and make a large market opportunity legible within minutes was not a rhetorical trick. It was genuine signal. Founders who could not articulate a clear vision simply and compellingly were, in this logic, founders who probably did not have one.

These two communication cultures evolved in parallel for decades, largely without needing to interact. Scientists wrote for scientists. Investors funded entrepreneurs who had, typically, already left academic culture behind. The collision came as university research became increasingly commercialisable — and as funding bodies, from the 1990s onward, began requiring researchers to demonstrate pathways to market impact as a condition of public grants. Suddenly, the people most deeply trained in one communication culture were being asked to perform in the other, with no training, no models, and no acknowledgement that the switch required anything more than goodwill and a slightly shorter presentation.

The structural mismatch plays out in specific, recurring patterns. Researchers lead with mechanism rather than problem — explaining how something works before establishing why anyone needs it to work. They use passive constructions and probabilistic language that investors read as uncertainty about the opportunity rather than appropriate scientific caution. They present data in the forms most meaningful to domain experts — forest plots, p-values, confidence intervals — rather than in the simplified metrics that allow a non-specialist to assess magnitude and significance quickly. And they almost universally underestimate the importance of the market slide: the moment in a pitch where a researcher must claim, with conviction, that they understand the commercial landscape their technology is entering.

The cost is asymmetric in ways that are rarely acknowledged openly. When an entrepreneur with a weaker technology but stronger communication skills secures funding ahead of a researcher with a stronger discovery but weaker pitch, the market has not made a good decision. It has made a presentation decision. The downstream consequences — a product pipeline that reflects what could be communicated rather than what was most worth developing — are diffuse, invisible, and largely untracked. No one audits the investment decisions not made. No one counts the diagnostics not developed, the materials not scaled, the treatments not funded because the researcher in the room could not find the sentence that would have changed the outcome.

For the individual researcher, repeated failure in the investment room carries a particular sting. Unlike a rejected paper — where the feedback is formalised, the criteria are understood, and a revision pathway exists — a failed pitch typically generates no actionable explanation. Investors decline politely and move on. The researcher is left to conclude, often incorrectly, that the problem was the science. The problem was almost never the science. It was the story around it, and the confidence with which that story was delivered.

This matters because confidence in a pitch is not the same as overconfidence about the underlying work. A researcher can speak with genuine conviction about the commercial opportunity, the market need, and the strategic path forward, while remaining entirely intellectually honest about the technical risks. The two registers are not in conflict. They simply require practice in combination — and that practice is almost never offered to researchers at the moment they need it most.

The solution has two components that are most powerful when delivered together. The first is the pitch deck itself — not a reformatted version of a conference poster, not an executive summary with better fonts, but a purpose-built investment narrative that opens with the problem, establishes the market, positions the technology as the most credible available solution, and makes a specific, defensible ask. Built by someone who understands both the science and the commercial logic it needs to inhabit, and who can translate between them without losing the integrity of either.

The second component is the researcher's own voice. A pitch deck that the researcher cannot inhabit convincingly is an expensive document. Personal coaching — iterative, honest, and calibrated specifically to how that researcher communicates — is what turns a presentation into a conversation, and a conversation into a closed investment. It builds the specific capability of speaking the language of data and market opportunity with the same authority a researcher already brings to a seminar room. Not a different person. The same person, trained for a different room.

The scientists who are failing in investment conversations are not failing because their work is insufficient. They are failing because no one ever told them that the room they were walking into had different rules — and that those rules can be learned. The discoveries are already there. What they need is someone who can help the researcher carry them across, in language the other side of the table recognises as the beginning of something worth funding.